TMU Professor Kuo-Hsiang Chuang Wins 2023 Best Bio CEO Award

Kuo-Hsiang Chuang, the CEO of CytoArm, a TMU-supported startup, has been honored with the Best Bio CEO Award by Global Bio & Investment Magazine in October 2023.

In addition to his role as CEO, Kuo-Hsiang Chuang serves as a professor at the TMU Graduate Institute of Pharmacognosy, specializing in antibody engineering, genetic engineering, and innovative technology development in immunotherapy. With 22 years of dedicated experience, Chaung led his team in creating a groundbreaking technology platform known as Armed-T, with the ambition of revolutionizing cancer treatment.

Chuang received an award from Global Bio & Investment

The innovative platform significantly reduces preparation time to just 10 days, providing patients with 4 to 6 doses of Armed-T cell therapy. Additionally, it eliminates the need for viruses or gene transfection techniques, mitigating the risk of virus contamination. Chuang noted that this platform surpasses current CAR-T therapy (Chimeric Antigen Receptor-T cell therapy) in terms of time, staffing, equipment cost, treatment effectiveness, and safety.

Driven by a commitment to excellence, Chuang founded CytoArm after the platform’s patent was approved in 2020. He assembled a team of outstanding experts, including a former director of the U.S. FDA (Food and Drug Administration), professionals with international drug authorization experience, and a CFO with experiences in domestic listed companies.

CytoArm’s first Armed-T cell product (CTA-02) is set to undergo further clinical trials in the first quarter of 2024. The focus would be on its application in treating colorectal cancer with EGFR mutation, an area currently lacking effective treatments. Looking ahead, CytoArm aims to advance the treatment of various solid tumors, such as pancreatic cancer, lung cancer, and triple-negative breast cancer, with the ultimate goal of providing more opportunities and hope in the fight against cancer.

The founding team of CytoArm